Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains.
Zabofloxacin, a new fluoroquinolone compound (DW-224a), was tested by reference agar dilution methods against 35 strains of multiresistant Neisseria gonorrhoeae. The potency of zabofloxacin (MIC(50), 0.016 microg/mL) was generally comparable with azithromycin but 8-fold superior to ciprofloxacin. This novel naphthyridine should be explored as an alternative therapy for quinolone-nonsusceptible gonorrhea and Chlamydia trachomatis infections.
Jones
Ronald N
RN
JMI Laboratories, North Liberty, IA 52317, USA. ronald-jones@jmilabs.com
Biedenbach
Douglas J
DJ
Ambrose
Paul G
PG
Wikler
Matthew A
MA
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones / Q000494:pharmacology*; D006069:Gonorrhea / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D015363:Quinolones / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D015363:Quinolones; C480202:zabofloxacin